A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine  

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.

Study with site having site user

Study with site having site user

t1

Test Study 2

Test Study 2

Prescreener  

Prescreener

TrialXAutomationRun6712

TrialXAutomationRun6712

test

test

test2

test2

Website search  

tewst

TrialXAutomationRun4323

TrialXAutomationRun4323